25th EADV Congress. Late-breaking insight: Tildrakizumab Phase 3 data in psoriasis
Автор: Dermatology Education
Загружено: 2016-10-03
Просмотров: 1419
Professor Kristian Reich provides insight into late-breaking data from a Phase 3 trial for tildrakizumab in patients with moderate to severe plaque psoriasis, presented at the 25th EADV Congress.
Find out more at: http://www.dermatology-education.com/...
View Professor Kristian Reich's profile at: http://www.dermatology-education.com/...
Dermatology Education is directed by internationally renowned experts in dermatology who will provide regular clinical perspectives on the latest publications, congress presentations, treatment guidelines and other information addressing the challenges faced by dermatologists in the clinic.
The views expressed here are those of the contributors and do not reflect those of either FIDE or The Fishawack Group of Companies. The content has been developed for specialist dermatologists only. It is intended to help them with their own professional development and research and should not be relied upon for making individual clinical decisions, which are the responsibility of the treating clinicians.
Participation by Professor Kristian Reich in this activity does not constitute or imply endorsement by the Georg-August-University or the Dermatologikum Hamburg.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
